<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01177813</url>
  </required_header>
  <id_info>
    <org_study_id>1245.20</org_study_id>
    <secondary_id>2009-016243-20</secondary_id>
    <nct_id>NCT01177813</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Phase III Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 and Sitagliptin Administered Orally Over 24 Weeks, in Drug na√Øve Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Diet and Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the efficacy, safety and tolerability of BI 10773
      compared to placebo and sitagliptin given for 24 weeks as monotherapy in patients with T2DM
      with insufficient glycaemic control. For the open-label part of the study the objective is to
      estimate the efficacy and safety of BI 10773 when given for 24 weeks in patients with T2DM
      with very poor glycaemic control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 24 Weeks</measure>
    <time_frame>Baseline and day 169</time_frame>
    <description>The term &quot;baseline&quot; refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm).
In this endpoint, the &quot;measured values&quot; show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Body Weight</measure>
    <time_frame>Baseline and day 169</time_frame>
    <description>The term &quot;baseline&quot; refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm).
In this endpoint, the &quot;measured values&quot; show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Systolic and Diastolic Blood Pressure (SBP and DBP)</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The term &quot;baseline&quot; refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm).
In this endpoint, the &quot;measured values&quot; show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive.
For blood pressure, data following changes in antihypertensive therapy is censored, in the same way that data following initiation of rescue medication is censored.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Confirmed Hypoglycaemic Adverse Events</measure>
    <time_frame>From first drug intake until 7 days after last medication intake, up to 219 days</time_frame>
    <description>Confirmed hypoglycaemic events refer to all hypoglycaemic events, that had a glucose value &lt;= 70 ml/dL or where assistance was required.
Symptomatic hypoglycaemic events were to be reported as adverse events. Patients can be counted in more than one category.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">986</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 10773 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive BI 10773 low dose tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive BI 10773 high dose tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive tablets identical to those containing BI 10773 low dose and high dose and to Sitagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive Sitagliptin 100 mg tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 high dose open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive BI 10773 high dose tablets open label once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical to BI10773 high dose</intervention_name>
    <description>placebo tablets once daily</description>
    <arm_group_label>BI 10773 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 low dose tablet once daily</description>
    <arm_group_label>BI 10773 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 open label</intervention_name>
    <description>Patients receive BI 10773 high dose tablets open label once daily</description>
    <arm_group_label>BI 10773 high dose open label</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical to BI10773 low dose</intervention_name>
    <description>placebo tablets once daily</description>
    <arm_group_label>BI 10773 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical to BI10773 low dose</intervention_name>
    <description>placebo tablets once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical to BI10773 high dose</intervention_name>
    <description>placebo tablets once daily</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical to Sitagliptin 100mg</intervention_name>
    <description>placebo tablets once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical to Sitagliptin 100mg</intervention_name>
    <description>placebo tablets once daily</description>
    <arm_group_label>BI 10773 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI10773</intervention_name>
    <description>BI 10773 high dose tablets once daily</description>
    <arm_group_label>BI 10773 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin tablets 100 mg once daily</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical to Sitagliptin 100mg</intervention_name>
    <description>placebo tablets once daily</description>
    <arm_group_label>BI 10773 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical to BI10773 low dose</intervention_name>
    <description>placebo tablets once daily</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical to BI10773 high dose</intervention_name>
    <description>placebo tablets once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of type 2 diabetes mellitus prior to informed consent;

          2. Male and female patients on diet and exercise regimen who are drug-na√Øve;

          3. HbA1c &gt;= 7.0% and &lt;= 10.0% at Visit 1 (screening) for randomised treatment; HbA1c &gt;
             10.0% at visit 1 (screening) for the open-label BI 10773 arm;

          4. Age &gt;= 20 (Japan); Age &gt;= 18 (countries other than Japan);

          5. BMI &lt;= 45 kg/m2 at Visit 1 (screening);

          6. Signed and dated written informed consent by date of Visit 1

        Exclusion criteria:

          1. Uncontrolled hyperglycaemia;

          2. Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or TIA
             within 3 months prior to informed consent;

          3. Indication of liver disease, either ALT, AST, or alkaline phosphatase above 3 x ULN;

          4. Impaired renal function (eGFR&lt;50 ml/min);

          5. Bariatric surgery within the past two years or other GI surgeries;

          6. Medical history of cancer;

          7. Contraindications to sitagliptin;

          8. Blood dyscrasias or any disorders causing haemolysis or unstable red blood cell;

          9. Treatment with any anti-diabetes drug within 12 weeks prior to randomisation;

         10. Treatment with anti-obesity drugs or any other treatment leading to unstable body
             weight;

         11. Current treatment with systemic steroids or change in dosage of thyroid hormones
             within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder
             except T2DM;

         12. Pre-menopausal women who are nursing or pregnant or are of child-bearing potential and
             not practicing an acceptable method of birth control;

         13. Alcohol or drug abuse;

         14. Intake of an investigational drug in another trial within 30 days prior to intake of
             study medication in this trial;

         15. Any other clinical condition that would jeopardize patients safety while participating
             in this clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.20.10124 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10150 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10154 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10131 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Northglenn</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10137 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10078 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10128 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fishers</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arkansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10146 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10144 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10129 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Carlisle</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10130 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gallipolis</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10089 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10151 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.10155 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.32008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.32011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.32023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>De Pinte</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.32015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deurne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.32016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deurne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.32025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goz√©e</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.32022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Landen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.32019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leopoldsburg</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.32024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linkebeek</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.32021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mouscron</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.32027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Retie</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.32020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sint-Gillis-Waas</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.32018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tielt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.32026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tremelo</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chilliwack</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strathroy</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlottetown</city>
        <state>Prince Edward Island</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montague</city>
        <state>Prince Edward Island</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.20021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trois Rivieres</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guiyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jingzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>QingDao</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shiyan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.86014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xiamen</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.49016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>D√ºsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.49015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.49019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haag</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.49020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hohenm√∂lsen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.49014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>K√∂then</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuwied</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>N√ºrnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.49022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schauenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.49017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Ingbert/Oberw√ºrzbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Unterschneidheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.91005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.91008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belgaum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.91009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai, Maharastra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.91010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tamil Nadu</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.35302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Co. Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.35305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Co. Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.35303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Co. Wexford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.35304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Offaly</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.35306 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wexford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.81007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiyoda-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.81001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.81002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.81005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ebetsu, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.81004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamakura, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.81003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minato-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.81006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.81008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.81009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.81010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ube, Yamaguchi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.81012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Urasoe, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.81013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Urasoe, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.41004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.20.41003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rorschach</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>Germany</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Japan</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2010</study_first_submitted>
  <study_first_submitted_qc>August 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2010</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 16, 2014</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients receive tablets identical to those containing 10 mg and 25 mg Empagliflozin and to Sitagliptin 100 mg once daily in the morning.</description>
        </group>
        <group group_id="P2">
          <title>Empagliflozin10 mg</title>
          <description>Patients receive 10 mg Empagliflozin in tablets once daily in the morning.</description>
        </group>
        <group group_id="P3">
          <title>Empagliflozin 25 mg</title>
          <description>Patients receive 25 mg Empagliflozin in tablets once daily in the morning.</description>
        </group>
        <group group_id="P4">
          <title>Sitagliptin 100 mg</title>
          <description>Patients receive 100 mg Sitagliptin in tablets once daily in the morning.</description>
        </group>
        <group group_id="P5">
          <title>Empagliflozin 25 mg OL</title>
          <description>Patients receive 25 mg Empagliflozin in tablets open label (OL) once daily in the morning.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
                <participants group_id="P2" count="224"/>
                <participants group_id="P3" count="224"/>
                <participants group_id="P4" count="223"/>
                <participants group_id="P5" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="206"/>
                <participants group_id="P3" count="204"/>
                <participants group_id="P4" count="206"/>
                <participants group_id="P5" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) including all randomised and treated patients who had a baseline HbA1c value (non-open label groups) and Open-label set including all patients entered in the empagliflozin 25 mg open-label treatment arm.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients receive tablets identical to those containing 10 mg and 25 mg Empagliflozin and to Sitagliptin 100 mg once daily in the morning.</description>
        </group>
        <group group_id="B2">
          <title>Empagliflozin10 mg</title>
          <description>Patients receive 10 mg Empagliflozin in tablets once daily in the morning.</description>
        </group>
        <group group_id="B3">
          <title>Empagliflozin 25 mg</title>
          <description>Patients receive 25 mg Empagliflozin in tablets once daily in the morning.</description>
        </group>
        <group group_id="B4">
          <title>Sitagliptin 100</title>
          <description>Patients receive 100 mg Sitagliptin in tablets once daily in the morning.</description>
        </group>
        <group group_id="B5">
          <title>Empagliflozin 25 mg OL</title>
          <description>Patients receive 25 mg Empagliflozin in tablets open label once daily in the morning.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="228"/>
            <count group_id="B2" value="224"/>
            <count group_id="B3" value="224"/>
            <count group_id="B4" value="223"/>
            <count group_id="B5" value="87"/>
            <count group_id="B6" value="986"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The descriptive statistics for Total refers to the 4 non-open label groups (Placebo, Empagliflozin 10mg and 25 mg, Sitagliptin)</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.9" spread="10.9"/>
                    <measurement group_id="B2" value="56.2" spread="11.6"/>
                    <measurement group_id="B3" value="53.8" spread="11.6"/>
                    <measurement group_id="B4" value="55.1" spread="9.9"/>
                    <measurement group_id="B5" value="50.2" spread="11.3"/>
                    <measurement group_id="B6" value="55.0" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="141"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 24 Weeks</title>
        <description>The term ‚Äúbaseline‚Äù refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm).
In this endpoint, the &quot;measured values&quot; show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive.</description>
        <time_frame>Baseline and day 169</time_frame>
        <population>FAS and open-label set, last observation carried forward (LOCF) was used as the imputation rule for both sets</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive tablets identical to those containing 10 mg and 25 mg Empagliflozin and to Sitagliptin 100 mg once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Patients receive 100 mg Sitagliptin in tablets once daily in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 25 mg OL</title>
            <description>Patients receive 25 mg Empagliflozin in tablets open label once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 24 Weeks</title>
          <description>The term ‚Äúbaseline‚Äù refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm).
In this endpoint, the &quot;measured values&quot; show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive.</description>
          <population>FAS and open-label set, last observation carried forward (LOCF) was used as the imputation rule for both sets</population>
          <units>percent of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="224"/>
                <count group_id="O4" value="223"/>
                <count group_id="O5" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.05"/>
                    <measurement group_id="O2" value="-0.66" spread="0.06"/>
                    <measurement group_id="O3" value="-0.77" spread="0.06"/>
                    <measurement group_id="O4" value="-0.65" spread="0.05"/>
                    <measurement group_id="O5" value="-3.10" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Model was adjusted for treatment,geographical region, and renal function at baseline as fixed effects, and baseline HbA1c as linear covariate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Difference calculated as empagliflozin 10mg minus placebo</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Model was adjusted for treatment,geographical region, and renal function at baseline as fixed effects, and baseline HbA1c as linear covariate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Difference calculated as empagliflozin 25mg minus placebo</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.01</ci_lower_limit>
            <ci_upper_limit>-0.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Body Weight</title>
        <description>The term ‚Äúbaseline‚Äù refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm).
In this endpoint, the &quot;measured values&quot; show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive.</description>
        <time_frame>Baseline and day 169</time_frame>
        <population>FAS (LOCF) and open-label set (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive tablets identical to those containing 10 mg and 25 mg Empagliflozin and to Sitagliptin 100 mg once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Patients receive 100 mg Sitagliptin in tablets once daily in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 25 mg OL</title>
            <description>Patients receive 25 mg Empagliflozin in tablets open label once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Body Weight</title>
          <description>The term ‚Äúbaseline‚Äù refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm).
In this endpoint, the &quot;measured values&quot; show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive.</description>
          <population>FAS (LOCF) and open-label set (LOCF)</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="224"/>
                <count group_id="O4" value="223"/>
                <count group_id="O5" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.15"/>
                    <measurement group_id="O2" value="-2.26" spread="0.19"/>
                    <measurement group_id="O3" value="-2.48" spread="0.18"/>
                    <measurement group_id="O4" value="0.17" spread="0.18"/>
                    <measurement group_id="O5" value="-1.93" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Model was adjusted for treatment,geographical region,and renal function at baseline as fixed effects,baseline body weight and baseline HbA1c as linear covariate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Difference calculated as empagliflozin 10mg minus placebo</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.48</ci_lower_limit>
            <ci_upper_limit>-1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Model was adjusted for treatment,geographical region,and renal function at baseline as fixed effects,baseline body weight and baseline HbA1c as linear covariate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Difference calculated as empagliflozin 25mg minus placebo</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.70</ci_lower_limit>
            <ci_upper_limit>-1.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Systolic and Diastolic Blood Pressure (SBP and DBP)</title>
        <description>The term ‚Äúbaseline‚Äù refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm).
In this endpoint, the &quot;measured values&quot; show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive.
For blood pressure, data following changes in antihypertensive therapy is censored, in the same way that data following initiation of rescue medication is censored.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>FAS and open-label set, last observation carried forward without values following a change in antihypertensive therapy (LOCF- H) was used as the imputation rule</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive tablets identical to those containing 10 mg and 25 mg Empagliflozin and to Sitagliptin 100 mg once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Patients receive 100 mg Sitagliptin in tablets once daily in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 25 mg OL</title>
            <description>Patients receive 25 mg Empagliflozin in tablets open label once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Systolic and Diastolic Blood Pressure (SBP and DBP)</title>
          <description>The term ‚Äúbaseline‚Äù refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm).
In this endpoint, the &quot;measured values&quot; show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive.
For blood pressure, data following changes in antihypertensive therapy is censored, in the same way that data following initiation of rescue medication is censored.</description>
          <population>FAS and open-label set, last observation carried forward without values following a change in antihypertensive therapy (LOCF- H) was used as the imputation rule</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="224"/>
                <count group_id="O4" value="223"/>
                <count group_id="O5" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.8"/>
                    <measurement group_id="O2" value="-3.5" spread="1.0"/>
                    <measurement group_id="O3" value="-3.2" spread="0.9"/>
                    <measurement group_id="O4" value="0.2" spread="0.9"/>
                    <measurement group_id="O5" value="-3.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.5"/>
                    <measurement group_id="O2" value="-1.1" spread="0.6"/>
                    <measurement group_id="O3" value="-1.7" spread="0.5"/>
                    <measurement group_id="O4" value="0.4" spread="0.5"/>
                    <measurement group_id="O5" value="-1.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Systolic Blood Pressure
Model was adjusted for treatment,geographical region, and renal function at baseline as fixed effects, baseline SBP and baseline HbA1c as linear covariate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0231</p_value>
            <p_value_desc>Difference calculated as empagliflozin 10mg minus placebo</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for Systolic blood pressure
Model was adjusted for treatment,geographical region, and renal function at baseline as fixed effects, baseline SBP and baseline HbA1c as linear covariate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0028</p_value>
            <p_value_desc>Difference calculated as empagliflozin 25mg minus placebo</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for diastolic blood pressure
Model was adjusted for treatment,geographical region, and renal function at baseline as fixed effects, baseline DBP and baseline HbA1c as linear covariate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3987</p_value>
            <p_value_desc>Difference calculated as empagliflozin 10mg minus placebo</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for diastolic blood pressure
Model was adjusted for treatment,geographical region, and renal function at baseline as fixed effects, baseline DBP and baseline HbA1c as linear covariate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0296</p_value>
            <p_value_desc>Difference calculated as empagliflozin 25mg minus placebo</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Confirmed Hypoglycaemic Adverse Events</title>
        <description>Confirmed hypoglycaemic events refer to all hypoglycaemic events, that had a glucose value &lt;= 70 ml/dL or where assistance was required.
Symptomatic hypoglycaemic events were to be reported as adverse events. Patients can be counted in more than one category.</description>
        <time_frame>From first drug intake until 7 days after last medication intake, up to 219 days</time_frame>
        <population>Treated set (actual) including all patients treated with at least 1 dose of randomised trial medication with some treatment switchers (1 from Empa25 to placebo; 1 patient got Empa 10 at least with one mis-allocated kit) and open-label set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive tablets identical to those containing 10 mg and 25 mg Empagliflozin and to Sitagliptin 100 mg once daily in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Patients receive 100 mg Sitagliptin in tablets once daily in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 25 mg OL</title>
            <description>Patients receive 25 mg Empagliflozin in tablets open label once daily in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Hypoglycaemic Adverse Events</title>
          <description>Confirmed hypoglycaemic events refer to all hypoglycaemic events, that had a glucose value &lt;= 70 ml/dL or where assistance was required.
Symptomatic hypoglycaemic events were to be reported as adverse events. Patients can be counted in more than one category.</description>
          <population>Treated set (actual) including all patients treated with at least 1 dose of randomised trial medication with some treatment switchers (1 from Empa25 to placebo; 1 patient got Empa 10 at least with one mis-allocated kit) and open-label set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="223"/>
                <count group_id="O5" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptomatic hypoglycaemic adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.4"/>
                    <measurement group_id="O4" value="0.4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymptomatic hypoglycaemic adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until seven days after last trial medication intake, up to 219 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients receive tablets identical to those containing 10 mg and 25 mg Empagliflozin and to Sitagliptin 100 mg once daily in the morning.</description>
        </group>
        <group group_id="E2">
          <title>Empagliflozin10 mg</title>
          <description>Patients receive 10 mg Empagliflozin in tablets once daily in the morning.</description>
        </group>
        <group group_id="E3">
          <title>Empagliflozin 25 mg</title>
          <description>Patients receive 25 mg Empagliflozin in tablets once daily in the morning.</description>
        </group>
        <group group_id="E4">
          <title>Sitagliptin 100 mg</title>
          <description>Patients receive 100 mg Sitagliptin in tablets once daily in the morning.</description>
        </group>
        <group group_id="E5">
          <title>Empagliflozin 25 mg OL</title>
          <description>Patients receive 25 mg Empagliflozin in tablets open label (OL) once daily in the morning.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Gilbert's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

